SY Investing on X: "$SAGE (-62% PM) announced pivotal Ph 3 MOUNTAIN results of SAGE-217 in MDD. Study didn't meet primary endpoint. #Fail SAGE-217 showed mean reduction of 12.6 in HAM-D total
sage-10k_20161231.htm
SAGE-217 Archives - MGH Center for Women's Mental Health
Zuranolone - Wikipedia
a SAGE-217 plasma concentration over time (SAD). Mean plasma... | Download Scientific Diagram
Zuranolone (SAGE-217) | GABAA Receptor Modulator | MedChemExpress
Biopharmaceutical Company for Brain Health Disorders - Sage Therapeutics
SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies | Clinical Pharmacokinetics
Zuranolone. GABAA receptor positive allosteric modulator, Treatment of major depressive disorder, Treatment of postpartum depres
SAGE-217 In Major Depressive Disorder: A Multi-Center, Randomized, Double-Blind, Phase 2 Placebo-Controlled Trial
SAGE-324 (GABA-A receptor positive allosteric modulator)
SAGE-217
SAGE-217 | Excenen PharmaTech
Development of Zuranolone (SAGE 217) for PPD Will Move Forward
Figure 1 from Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid)A Receptor ...
Sage advice: psychiatric drug development is tough | Evaluate
Revisiting SAGE, climbing up the MOUNTAIN | by Sys2Research | Medium
SAGE-217 (S-812217, SGE 797, CAS Number: 1632051-40-1) | Cayman Chemical
a SAGE-217 plasma concentration over time (SAD). Mean plasma... | Download Scientific Diagram
Health-Related Quality of Life In A Phase 2, Randomized, Placebo-Controlled Trial Of The GABA R Modulator SAGE-217 in Major Depr
Zuranolone (SAGE-217)|CAS 1632051-40-1|DC Chemicals
